Gedeon Richter Agrees to Buy Mayne Pharma

Suppliers and distributors of Mayne Pharma's medicines should watch shareholder approval and the Evaris divestiture before assuming ownership changes.

Updated on Nov. 17, 2026 in Healthcare

Gedeon Richter Agrees to Buy Mayne Pharma

Hungarian drugmaker Gedeon Richter has agreed to acquire a 100% stake in Mayne Pharma for $6.40 per share under a scheme implementation deed. The deal is subject to shareholder approval and completion of Mayne Pharma's pending sale of its international business to Evaris Pharma, so pharmaceutical operators tracking consolidation should watch both conditions.

Why it matters

The offer carries a 99.4% premium to Mayne Pharma's closing price on 16 November and a 124% premium to its 30-day volume weighted average price, a signal of how much an acquirer is willing to pay to take full control of a listed generic and specialty drug company. Mayne Pharma's board has unanimously recommended the scheme to shareholders absent a superior proposal.

The offer of $6.40 per share is a 99.4% premium to Mayne Pharma's 16 November closing price and a 124% premium to its 30-day volume weighted average price. The scheme is fully funded and would transfer 100% of Mayne Pharma to Gedeon Richter if approved.

The players

Gedeon Richter

Hungarian multinational drugmaker with a broad portfolio of pharmaceutical products across women's health, cardiovascular, and central nervous system therapeutic areas.

Mayne Pharma

Australian-listed pharmaceutical company whose business spans generic and specialty medicines, and which is in the process of divesting its international business segment.

Evaris Pharma

Pharmaceutical company acquiring Mayne Pharma's international business segment under a previously announced transaction that is a condition of the scheme.

The details

Under a scheme of arrangement, Gedeon Richter would acquire all shares of Mayne Pharma through a court-supervised process rather than a conventional tender offer. The transaction is conditional on shareholder approval at the scheme meeting and on Mayne Pharma first completing its previously announced sale of its international business segment to Evaris Pharma. Because the scheme is fully funded, completion depends on those approvals and conditions rather than on financing.

Timeline

  1. 16 November: Closing price used as the basis for the offer's premium calculations.

  2. Scheme meeting: Date not specified in the source; shareholder vote required before completion.

Market Landscape

Acquisitions of listed generic drugmakers by European pharmaceutical groups have become a recurring way for buyers to add established product portfolios without building them organically. The Gedeon Richter and Mayne Pharma transaction follows that pattern, with the sale of Mayne Pharma's international segment to Evaris Pharma reshaping what the buyer actually acquires.

Operators in pharmaceutical distribution and generic supply should monitor whether Mayne Pharma's product lines and supplier relationships change once ownership moves to Gedeon Richter. Procurement teams dealing with Mayne Pharma should watch the Evaris Pharma divestiture, since it determines which assets remain under the new owner.

The takeaway

Ownership and product-line changes in a acquired generic drugmaker can affect supply contracts, so suppliers and distributors should review their agreements once the scheme is approved and the Evaris divestiture closes. Track the scheme meeting outcome and the completion of the Evaris transaction as the two gating events for this deal.

Further reading

For context on how drug companies are reshaping their portfolios through Healthcare deals, see the sector's ongoing coverage.